Ilya Rachman
Algemeen Directeur bij IMMIX BIOPHARMA, INC.
Vermogen: 2 M $ op 30-04-2024
Actieve functies van Ilya Rachman
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| IMMIX BIOPHARMA, INC. | Algemeen Directeur | 01-01-2012 | - |
| Voorzitter | 01-01-2012 | - | |
| Oprichter | 01-01-2012 | - | |
Nexcella, Inc.
 Nexcella, Inc. BiotechnologyHealth Technology Part of Immix Biopharma, Inc., Nexcella, Inc. is a clinical-stage biopharmaceutical company based in Los Angeles, CA. The company is engaged in the discovery and development of novel cell therapies for oncology and other indications. Nexcella's lead candidate, next generation bcma-targeted car-t nxc-201, has produced high response rates in relapsed/refractory al amyloidosis and relapsed/refractory multiple myeloma, and has been awarded orphan drug designation by the FDA in both indications. The company's n-genius platform allows for the discovery, development, and manufacture of cutting-edge cell therapies for patients in need. Expansion into autoimmune indications is planned. | Voorzitter | - | - |
Loopbaan van Ilya Rachman
Opleiding van Ilya Rachman
| University of Illinois | Doctorate Degree |
| University of Iowa | Undergraduate Degree |
| University of California, Los Angeles | Masters Business Admin |
Statistieken
Internationaal
| Verenigde Staten | 6 |
Operationeel
| Chairman | 2 |
| Chief Executive Officer | 1 |
| Founder | 1 |
Sectoraal
| Consumer Services | 4 |
| Health Technology | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| IMMIX BIOPHARMA, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Nexcella, Inc.
Nexcella, Inc. BiotechnologyHealth Technology Part of Immix Biopharma, Inc., Nexcella, Inc. is a clinical-stage biopharmaceutical company based in Los Angeles, CA. The company is engaged in the discovery and development of novel cell therapies for oncology and other indications. Nexcella's lead candidate, next generation bcma-targeted car-t nxc-201, has produced high response rates in relapsed/refractory al amyloidosis and relapsed/refractory multiple myeloma, and has been awarded orphan drug designation by the FDA in both indications. The company's n-genius platform allows for the discovery, development, and manufacture of cutting-edge cell therapies for patients in need. Expansion into autoimmune indications is planned. | Health Technology |
- Beurs
- Insiders
- Ilya Rachman
- Ervaring
